In a nutshell This trial is evaluating the safety and effectiveness of allogeneic CAR-T cell therapy (ALLO-715) in patients with multiple myeloma (MM) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This trial is recruiting in Denver, CO. The details Chimeric...
Read More
In a nutshell This trial will compare the effectiveness of two maintenance therapies in patients with multiple myeloma (MM) after a stem cell transplant (SCT). The main outcome to be measured will be the average time from treatment until death due to any cause. The details Maintenance therapy is commonly given after SCT to help delay...
Read MoreIn a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors. They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...
Read More
In a nutshell This study compared the effectiveness of Kd (carfilzomib, dexamethasone) chemotherapy to Vd (bortezomib, dexamethasone) chemotherapy in patients with multiple myeloma (MM). This study found that Kd improved survival outcomes and had fewer side effects compared to Vd chemotherapy for these patients. Some background Multiple...
Read More
In a nutshell This study evaluated the safety and effectiveness of the herpes zoster vaccine (Shingrix) in patients with blood cancer who are receiving anti-cancer therapy. This study concluded that the Shingrix vaccine was effective in these patients, with manageable side effects. Some background Shingles is caused by a virus called herpes zoster....
Read More
In a nutshell This study evaluated CyBorD (cyclophosphamide, bortezomib, dexamethasone) with or without a switch to another regimen mid-treatment for elderly patients with multiple myeloma (MM). The authors concluded that CyBorD was promising for these patients and that switching to VTD chemotherapy during treatment provided better...
Read More
In a nutshell This study is examining the effectiveness of antibody drug tiragolumab with or without standard treatment for relapsed or unresponsive multiple myeloma or non-Hodgkin lymphoma. The main outcome would be the side effects experienced by patients 1 year after treatment. The details Both multiple myeloma (MM) and non-Hodkin lymphoma...
Read More
In a nutshell This study investigated whether a combination of bortezomib (Velcade), melphalan (Alkeran) and prednisone (Deltasone) was more effective than lenalidomide (Revlimid) and dexamethasone (Decadron) followed by lenalidomide maintenance for newly diagnosed multiple myeloma (MM). The main finding was that age and disease risk influenced the...
Read More
In a nutshell This trial is investigating the effectiveness and side effects of nivolumab (Opdivo) with a dendritic cell vaccine for patients with multiple myeloma (MM). The main outcome of this study would be to see the number of patients that develop an allergic reaction to the treatment. This study is recruiting in Boston, MA, United...
Read MoreIn a nutshell This study is looking for patients with newly diagnosed multiple myeloma (MM) to try different treatment regimens. The main outcome that will be measured is the number of patients who do not experience cancer worsening after treatment. This trial is recruiting in Chicago, Illinois, United States. The details There are several...
Read More
In a nutshell This study investigated female fertility preservation (FFP) in cancer patients. They found that FFP should be discussed with all women of reproductive age undergoing cancer treatment. Some background Cancer can have many negative effects on patient health. Infertility is a particular concern for younger female patients....
Read More
In a nutshell This study aimed to investigate the maximum tolerated dose of carfilzomib plus melphalan and prednisone (KMP regimen) in patients with newly diagnosed elderly patients with multiple myeloma (MM). This study concluded that the maximum tolerated dose of carfilzomib was...
Read More
